Regulus Therapeutics, a microRNA-focused drug developer, has added to its impressive roster of pharmaceutical partners by signing a new deal with AstraZeneca.
Under the agreement, which covers three programmes focused on cardiovascular and metabolic diseases and oncology that are currently in preclinical...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
